Recent Updates
Recently added Catalysts
ALT

Altimmune Announces Important Additions to its Patent Portfolio for HepTcell and ALT-702 Programs

Wednesday, June 5, 2019 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Altimmune Announces Important Additions to its Patent Portfolio for HepTcell and ALT-702 Programs

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+22%
120-day peak, hindsight
Typical move
10.2%
average across 8 past catalysts
Cash runway
~64 mo
Minimal dilution risk
Lead asset
ALT-801
Phase 2 · Obesity/Overweight

Full Press Release Details

Altimmune Announces Important Additions to its Patent Portfolio for HepTcell and ALT-702 Programs.
ShareAdd on Google
Tags: ALT Viatris Investor Conferences Healthcare investor conferences healthcare conferences UBS Global Healthcare
Last updated: Jun 5, 2019

Biotech snapshot

Cash runway
$519M liquidity · $8M/mo burn
~64 mo
Minimal dilution risk
Lead asset
ALT-801Phase 2
Obesity/Overweight →

Catalyst track record

+22%
best trade around ALT's most recent catalyst

Peak hindsight return over a 120-day window, across 8 tracked FDA/PDUFA catalysts for ALT.

See every catalyst's timing & PoA →